Jubilant LifeScience has informed that material wholly-owned subsidiary, Jubilant Pharma (JPL) has given notice to the holders of its $300,000,000 4.875% Senior Notes due 2021 (the Notes) that it has elected to exercise its option to redeem $100,000,000 in aggregate principal amount of the Notes on November 20, 2019 (the Redemption Date) pursuant to the terms of the indenture dated as of October 6, 2016 (the Indenture) between JPL and The Bank of New York Mellon, London Branch as trustee, governing the Notes. Pursuant to the terms of the Indenture, the redemption price for the Notes will be equal to 102.43750% of the principal amount of such Notes, plus accrued and unpaid interest thereon, to (but not including) the Redemption Date (the Redemption Price). The Notes will be redeemed on a pro rata basis. The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: